Roche Sees Oncology Access Programs Key To Growth

17 Sep 2015

Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.

Producing safe and highly effective anticancer therapies is only part of the new drug development equation, and ensuring patients’ access to them is equally, if not more, important for pharma companies operating in today’s environment.

As governments around the world, squeezed by ballooning medical expenditures, increase their scrutiny of drug prices, major manufacturers like